Physician

Daniel Kevin Lavie, M.D.

According to 2025 Medicare claims, Daniel Lavie, M.D. (NPI: 1023374659) practices hematology/oncology in the Baton Rouge, LA market, with the plurality of this provider's patient population coming from E. Baton Rouge, LA. This provider's primary affiliated billing organization is MARY BIRD PERKINS CANCER CENTER (NPI: 1295833580; TIN: 237010520) and primary practice location at 70809-3482.

Lavie's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 414 traditional Medicare patients, billed 180,197 HCPCS/CPT codes, and received $3,418,557 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 2,273 prescription claims across 411 beneficiaries totaling $5,331,919 in drug costs, led by Lenalidomide (Lenalidomide). DME data shows 75 claims. Open Payments data shows 66 records totaling $1,394. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $2,801 to $3,418,557. Similarly, Part D prescription costs have moved sharply higher in recent years, from $9,339 to $5,331,919. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	22	40	$2,801
2017	17	31	$1,955
2018	95	228	$19,524
2019	261	1,245	$100,244
2020	275	1,464	$125,040
2021	287	1,526	$156,862
2022	346	139,235	$2,502,892
2023	381	181,375	$3,107,575
2024	414	180,197	$3,418,557

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	31	180	$9,339
2016	11	22	$784
2017	15	16	$222
2018	51	144	$81,084
2019	202	1,052	$1,007,014
2020	273	1,694	$1,701,123
2021	297	1,974	$2,237,372
2022	329	1,917	$2,630,504
2023	331	1,958	$3,257,123
2024	411	2,273	$5,331,919

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	24	$786
2020	N/R	84	$5,696
2021	N/R	69	$5,199
2022	N/R	38	$1,625
2023	N/R	37	$7,042
2024	N/R	75	$2,495

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	69	69	$158
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	176	785	$131
96413	Administration of chemotherapy into vein, 1 hour or less	72	418	$90
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	277	695	$86
96375	Injection of additional new drug or substance into vein	56	536	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	68	1,820	$910,489
Brukinsa	Zanubrutinib	38	1,140	$541,591
Tasigna	Nilotinib Hcl	25	700	$530,127
Revlimid	Lenalidomide	17	469	$300,419
Kisqali	Ribociclib Succinate	18	504	$252,688

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	19	$980
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	14	$878
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	15	$245
E0431	Portable gaseous oxygen system, rental; includes portable container, regulator, flowmeter, humidifier, cannula or mask, and tubing	Y	N/R	14	$229
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	13	$163

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	66	$1,394	Medtronic, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Daniel Kevin Lavie, M.D.?

Tedicare shows public-source Medicare data for Daniel Kevin Lavie, M.D. (NPI 1023374659), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Daniel Kevin Lavie, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Daniel Kevin Lavie, M.D.?

Daniel Kevin Lavie, M.D. is linked to MARY BIRD PERKINS CANCER CENTER (billing NPI 1295833580) in the available physician profile data.

Does Daniel Kevin Lavie, M.D. have Open Payments data?

Daniel Kevin Lavie, M.D. has 66 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.